CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Peter Maag sold 10,000 shares of the stock in a transaction on Monday, July 7th. The shares were sold at an average price of $18.58, for a total transaction of $185,800.00. Following the transaction, the director owned 308,846 shares in the company, valued at $5,738,358.68. This trade represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Peter Maag also recently made the following trade(s):
- On Tuesday, June 17th, Peter Maag sold 10,000 shares of CareDx stock. The shares were sold at an average price of $19.24, for a total transaction of $192,400.00.
- On Wednesday, April 30th, Peter Maag sold 13,281 shares of CareDx stock. The stock was sold at an average price of $17.23, for a total transaction of $228,831.63.
CareDx Stock Down 1.8%
CDNA traded down $0.37 during midday trading on Friday, hitting $20.26. 407,534 shares of the company were exchanged, compared to its average volume of 921,544. CareDx, Inc. has a 1-year low of $14.09 and a 1-year high of $34.84. The firm's 50 day moving average price is $17.99 and its 200-day moving average price is $19.71. The firm has a market capitalization of $1.13 billion, a P/E ratio of 17.57 and a beta of 2.19.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The business's revenue for the quarter was up 17.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.03) EPS. On average, sell-side analysts predict that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several analysts recently commented on CDNA shares. Stephens reissued an "overweight" rating and set a $40.00 target price on shares of CareDx in a research note on Monday, May 5th. Wall Street Zen downgraded shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research report on Monday, May 5th. Finally, The Goldman Sachs Group lowered their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $30.33.
Get Our Latest Research Report on CareDx
Institutional Trading of CareDx
A number of institutional investors have recently made changes to their positions in CDNA. Sterling Capital Management LLC raised its holdings in CareDx by 771.2% in the fourth quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock worth $27,000 after purchasing an additional 1,126 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in CareDx by 553.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after purchasing an additional 3,322 shares during the last quarter. State of Wyoming purchased a new position in CareDx in the fourth quarter worth about $91,000. PNC Financial Services Group Inc. lifted its position in shares of CareDx by 20,200.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 4,466 shares of the company's stock valued at $79,000 after buying an additional 4,444 shares in the last quarter. Finally, Morse Asset Management Inc purchased a new position in shares of CareDx during the 1st quarter valued at about $103,000.
About CareDx
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Further Reading

Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.